Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine Plus Subcutaneous Rituximab in DLBCL-type PTLD
NCT02753062Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD) and diffuse large B-cell lymphoma (DLBCL), sponsored by Asan Medical Center. Primary endpoint: Complete Response Rate. Status: unknown.
02
Drugs
bendamustinerituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02753062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753062.